Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.85 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.85 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.72 |
| ▸ | LSS | P48449 | 1/20 | 0.64 |
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 3/20 | 0.61 |
| ▸ | PKM | P14618 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5250380 | 0.92 | HSD11B1 (0.78) | MEN1KMT2AHSD11B1LSSATM | |
| SCHEMBL10985823 | 0.85 | MEN1 (0.85) | MEN1KMT2AHSD11B1HTTPKM | |
| SCHEMBL24477692 | 0.85 | MEN1 (0.85) | MEN1KMT2AHSD11B1HTTPKM | |
| SCHEMBL5251036 | 0.85 | MAPT (0.75) | MEN1KMT2AHSD11B1LSSATM | |
| SCHEMBL2839187 | 0.85 | MEN1 (0.85) | MEN1KMT2AHSD11B1HTTPKM | |
| SCHEMBL10722295 | 0.84 | KMT2A (0.84) | MEN1KMT2AHSD11B1HTTPKM | |
| SCHEMBL2963235 | 0.84 | ALDH1A1 (0.72) | MEN1KMT2AHSD11B1LSSATM | |
| SCHEMBL9312258 | 0.83 | PKM (0.68) | MEN1KMT2AHSD11B1HTTPKM | |
| SCHEMBL5327436 | 0.83 | HSD11B1 (0.65) | MEN1KMT2AHSD11B1LSSATM | |
| SCHEMBL5256269 | 0.82 | THRB (0.73) | MEN1KMT2AHSD11B1LSSATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1758884-A2 | N-CYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE | Elan Pharmaceuticals, Inc. (US) | 2007-03-07 | — | — | EP | claimed |
| US-20060035884-A1 | N-cyclic sulfonamido inhibitors of gamma secretase | ELAN PHARMACEUTICALS, INC. (US) | 2006-02-16 | — | — | US | claimed |
| WO-2005113542-A2 | N-CYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE | ELAN PHARMACEUTICALS, INC. (US) | 2005-12-01 | — | — | WO | claimed |
| US-20060035884-A1 | N-cyclic sulfonamido inhibitors of gamma secretase | ELAN PHARMACEUTICALS, INC. (US) | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035884-A1 | N-cyclic sulfonamido inhibitors of gamma secretase | BACE1, BACE2, APH1B | MEN1 2423/4885KMT2A 3354/4885HSD11B1 1013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.